Committed to sharing our science

387 results available

A Study to Evaluate Safety, Tolerability and Clinical Outcomes Following Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis

Poster, 22nd International Symposium on ALS/MND
Sydney, Australia
Shefner J, Brooks BR, Simmons Z, Mitsumoto H, Wolff AA, Lee JH, Jones DS, Mao J, Meng L, Cedarbaum JM, The CY 4024 Investigator Group
November 2011
The ALSFRS @ 20: Evolution of the ALSFRS-R History, Clinimetric Properties and Future Directions

Poster, 22nd International Symposium on ALS/MND
Sydney, Australia
Cedarbaum JM, Mitsumoto H, Pestronk A, Ringel S, Florence J, Sanjak M, Brooks BR
November 2011
Cardiac Myosin Activation Part 1: From Concept to Clinic

Journal of Molecular and Cellular Cardiology
Malik FI, Morgan BP
October 2011
The Effects of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Cardiac Function in Systolic Heart Failure: a Double-blind, Placebo-controlled, Crossover, Dose-ranging Phase 2 Trial

The Lancet
Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T
August 2011
Dose-dependent Augmentation of Cardiac Systolic Function with the Selective Cardiac Myosin Activator, Omecamtiv Mecarbil: a First-in-man Study

The Lancet
Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB
August 2011